Physician profile
Mark Sullivan
NPI 1225075328
$2,382.64
in general payments reported to CMS, 2019-2025
15 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $898 · 2023: $657 · 2024: $308 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $831.35 | 2022 | |
| Abiomed | $381.03 | 2023-2025 | Impella |
| Janssen Pharmaceuticals, INC | $316.29 | 2023-2024 | Xarelto |
| Silk Road Medical, INC. | $158.55 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Sanofi-Aventis U.S. LLC | $148.27 | 2023 | |
| Getinge USA Sales, LLC | $126.98 | 2021-2023 | Heartstring III Proximal Seal |
| Lemaitre Vascular, INC. | $124.76 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.19 | 2021 | |
| Boston Scientific Corporation | $48.82 | 2023 | |
| Edwards Lifesciences Corporation | $41.54 | 2022-2024 | Mitris Resilia Mitral Valve |
| Grifols USA, LLC | $30.93 | 2023 | Thrombate III |
| Atricure, INC. | $26.68 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $22.09 | 2024 | |
| Stryker Corporation | $16.61 | 2024 | Lucas |
| Ethicon US, LLC | $13.55 | 2025 | Vistaseal, Surgiflo Hemostatic Matrix, Surgicel Nu-Knit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.